• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类免疫缺陷病毒感染的细胞表面补体的激活。

Activation of complement on the surface of cells infected by human immunodeficiency virus.

作者信息

Spear G T, Landay A L, Sullivan B L, Dittel B, Lint T F

机构信息

Department of Immunology/Microbiology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612.

出版信息

J Immunol. 1990 Feb 15;144(4):1490-6.

PMID:1968081
Abstract

Cells were infected with HIV-1 and tested for C activation using a flow cytometric assay for bound C3 fragments. HIV-infected H9 cells bound increased levels of C3 using normal human serum as a C source only after cells were first incubated with serum containing anti-HIV antibody. Uninfected H9 cells or infected cells incubated with HIV-antibody negative sera did not bind C3. Although C3 bound quickly and was maximal within 10 min, modulation of bound C3 was slow with about 50% loss after 4 h. C3 binding required specific anti-HIV antibody, was blocked by EGTA, and did not occur in C2-deficient serum suggesting that binding was via the classical pathway. The HTLV-1-infected MT-4 cell line also bound high levels of C3 after coinfection with HIV. C3 binding in HIV-infected MT4 cells was also mediated via the classical pathway because it was not observed in Mg-EGTA chelated or C2-deficient sera. However, this classical pathway activation appeared to be antibody independent because it was also detected in HIV-antibody negative serum and a-gamma-globulinemic serum. This indicates that coinfection with HTLV-1 and HIV-1 can produce novel C activating conditions. No cytotoxic effect of human C for antibody-treated HIV-infected cells was observed in a chromium release assay. However, rabbit C was cytotoxic for HIV-infected cells in the absence of anti-HIV antibodies. Our results suggest that C can be activated in vivo by infected cells via specific anti-HIV antibody. The resultant C3 deposition on infected cells could have profound effects on interaction with CR-bearing cells.

摘要

细胞用HIV-1感染,并使用针对结合的C3片段的流式细胞术检测补体(C)激活情况。仅在细胞先用含抗HIV抗体的血清孵育后,以正常人血清作为补体来源时,HIV感染的H9细胞结合的C3水平才会增加。未感染的H9细胞或用HIV抗体阴性血清孵育的感染细胞不结合C3。尽管C3结合迅速且在10分钟内达到最大值,但结合的C3的调节较慢,4小时后约有50%损失。C3结合需要特异性抗HIV抗体,被乙二醇双四乙酸(EGTA)阻断,且在C2缺陷血清中不发生,这表明结合是通过经典途径进行的。人嗜T淋巴细胞病毒1型(HTLV-1)感染的MT-4细胞系在与HIV共感染后也结合高水平的C3。HIV感染的MT4细胞中的C3结合也通过经典途径介导,因为在镁-EGTA螯合血清或C2缺陷血清中未观察到。然而,这种经典途径激活似乎与抗体无关,因为在HIV抗体阴性血清和无丙种球蛋白血症血清中也检测到了。这表明HTLV-1和HIV-1共感染可产生新的补体激活条件。在铬释放试验中未观察到人补体对抗体处理的HIV感染细胞的细胞毒性作用。然而,在没有抗HIV抗体的情况下,兔补体对HIV感染细胞具有细胞毒性。我们的结果表明,补体可在体内被感染细胞通过特异性抗HIV抗体激活。由此产生的C3在感染细胞上的沉积可能对与携带补体受体(CR)的细胞的相互作用产生深远影响。

相似文献

1
Activation of complement on the surface of cells infected by human immunodeficiency virus.人类免疫缺陷病毒感染的细胞表面补体的激活。
J Immunol. 1990 Feb 15;144(4):1490-6.
2
A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.一种补体抗性的HeLa细胞系(T638)在C3沉积步骤受阻。
J Immunol. 1987 May 15;138(10):3385-91.
3
Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.感染者血清中针对HIV-1 V3环的抗体在包括补体激活、抗体结合和中和作用在内的免疫效应功能中占主要比例。
Virology. 1994 Nov 1;204(2):609-15. doi: 10.1006/viro.1994.1575.
4
Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).来自受感染个体和接种疫苗志愿者血清中的补体激活抗体,这些抗体靶向1型人类免疫缺陷病毒至1型补体受体(CR1,CD35)。
Virology. 1996 Dec 1;226(1):13-21. doi: 10.1006/viro.1996.0623.
5
Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.细菌对补体介导杀伤的抗性机制研究。V. IgG和F(ab')2通过替代补体途径介导对大肠杆菌O111B4的杀伤,而不增加C5b-9沉积。
J Immunol. 1983 Nov;131(5):2563-9.
6
Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.接种疫苗的猕猴血清中的抗细胞抗体可诱导补体介导的人免疫缺陷病毒和猴免疫缺陷病毒的病毒溶解。
Virology. 1993 Aug;195(2):475-80. doi: 10.1006/viro.1993.1398.
7
Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.经典途径激活的表面调节:绵羊、豚鼠和人红细胞上C2和C3转化酶的形成与调节
J Immunol. 1983 Jul;131(1):403-8.
8
Humoral immunostimulation. IV. Role of complement.体液免疫刺激。IV. 补体的作用。
J Exp Med. 1975 Apr 1;141(4):736-52.
9
CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.CR2是一种补体激活剂,也是Raji细胞在替代途径激活过程中C3的共价结合位点。
J Immunol. 1988 Mar 15;140(6):1923-9.
10
Activation of human complement by IgG antisperm antibody and the demonstration of C3 and C5b-9-mediated immune injury to human sperm.IgG抗精子抗体激活人补体及C3和C5b-9介导的对人精子的免疫损伤的证明
J Immunol. 1991 Jan 15;146(2):611-20.

引用本文的文献

1
Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.抗 HIV-1 抗体触发感染细胞上的非溶细胞补体沉积。
EMBO Rep. 2020 Feb 5;21(2):e49351. doi: 10.15252/embr.201949351. Epub 2019 Dec 12.
2
Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV.疫苗诱导的 V1V2 特异性抗体可控制和/或预防 HIV、SIV 和 SHIV 的感染。
Curr Opin HIV AIDS. 2019 Jul;14(4):309-317. doi: 10.1097/COH.0000000000000551.
3
A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.
一种用于检测针对感染 HIV-1 或 SIV 细胞的抗体依赖细胞介导的细胞毒性的新方法显示,与中和和结合测定中测量的抗体不完全重叠。
J Virol. 2012 Nov;86(22):12039-52. doi: 10.1128/JVI.01650-12. Epub 2012 Aug 29.
4
B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.淋巴结和外周血中的B淋巴细胞对于结合含有HIV-1的免疫复合物至关重要。
Immunology. 1999 Apr;96(4):612-9. doi: 10.1046/j.1365-2567.1999.00304.x.
5
Pathogenesis of human immunodeficiency virus infection.人类免疫缺陷病毒感染的发病机制
Microbiol Rev. 1993 Mar;57(1):183-289. doi: 10.1128/mr.57.1.183-289.1993.
6
Enhancing role of complement in HIV infection.补体在HIV感染中的增强作用。
Clin Exp Immunol. 1994 Aug;97 Suppl 2(Suppl 2):9-11. doi: 10.1111/j.1365-2249.1994.tb06255.x.
7
Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells.HIV感染细胞激活补体的HIV特异性及“抗体非依赖”机制的功效。
Clin Exp Immunol. 1995 Feb;99(2):189-95. doi: 10.1111/j.1365-2249.1995.tb05531.x.
8
Complement activation by human monoclonal antibodies to human immunodeficiency virus.针对人类免疫缺陷病毒的人源单克隆抗体引发的补体激活
J Virol. 1993 Jan;67(1):53-9. doi: 10.1128/JVI.67.1.53-59.1993.
9
Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.HIV-1感染患者血清中抗体依赖性补体介导的细胞毒性受CD55和CD59调控。
J Clin Invest. 1995 Sep;96(3):1520-6. doi: 10.1172/JCI118190.
10
Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease.CD8 + T细胞对HIV复制的抑制作用与CD4细胞计数及疾病临床分期相关。
Clin Exp Immunol. 1994 Jul;97(1):68-75. doi: 10.1111/j.1365-2249.1994.tb06581.x.